Incidental Axillary Coverage Comparison Between 3DCRT and Hybrid IMRT for Whole Breast Irradiation

Abstract

21%), ER (P 47%, N 42%, unknown 11%); PgR (P 58%, N 32%, unknown 11%);EGFR score (0 72.2%, 1+ 27.7%) ; HER2 score (0 10.5%, 1+ 21%, 2+ 42.1%, 3+ 26.3%); GEP100 (1+ 57.9%, 2+ 42.1%); AMAP1(1+ 73.7%, 2+ 26.3%). For TRR, HR of each markers EGFR 1+, HE2 3+, GEP100 2+ and AMAP1 2+ were 2.17 (95% CI 0.71 -6.57; p 0.17), 2.51 (0.47-13.4; 0.28), 1.23 (0.48-3.14; 0.67) and 1.27 (0.4-4.03; 0.68) respectively. The Table shows the HR for TRR of combination of several markers. Existence of co-overexpression of GEP100 with EGFR has trend to early recurrence. None of following factors; margin status (N vs. P/C p Z 0.48 Log-Rank test), ER status (N vs. P; 0.58), PgR status (N vs. P; 0.32) and age (<50 vs 50 0.97), correlated with TRR. Conclusions: Consistent with a notion that expression of EGFR or HER2 is a bad prognosis factor, our study reveals that their expression indeed correlates with early recurrences of tumors after BCT. Our study moreover indicates that co-expression of components of GEP100-Arf6-AMAP1 pathway with these receptor tyrosine kinases remarkably increases risks of the early recurrence of BCT. Author Disclosure: R. Kinoshita: None. J. Nam: None. M. Hosoda: None. K. C. Kubota: None. M. Tanino: None. A. Hashimoto: None. Y. M Ito: None. S. Tanaka: None. H. Sabe: None. H. Shirato: None.